29.71

0.87% -0.26

Alkermes Plc (ALKS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ALKS? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$29.97

Offen:

$29.76

24-Stunden-Volumen:

4.15M

Relative Volume:

2.40

Marktkapitalisierung:

$4.81B

Einnahmen:

$1.51B

Nettoeinkommen (Verlust:

$333.35M

KGV:

23.96

EPS:

1.24

Netto-Cashflow:

$315.22M

1W Leistung:

-2.62%

1M Leistung:

+6.45%

6M Leistung:

+18.60%

1J Leistung:

+9.31%

1-Tages-Spanne:

$29.53

$30.37

1-Wochen-Bereich:

$29.53

$31.18

52-Wochen-Spanne:

$22.90

$32.88

Alkermes Plc Stock (ALKS) Company Profile

Firmenname

Alkermes Plc

Sektor

Healthcare (1176)

Branche

Drug Manufacturers - Specialty & Generic (84)

Telefon

00-353-1-772-8000

Adresse

CONNAUGHT HOUSE, DUBLIN 4

Mitarbeiter

2,100

Twitter

@alkermes

Nächster Verdiensttermin

2024-10-24

Neueste SEC-Einreichungen

ALKS's Discussions on Twitter

Vergleichen Sie ALKS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALKS Alkermes Plc	29.71	4.81B	1.51B	333.35M	315.22M	1.95
ZTS Zoetis Inc	164.84	74.37B	9.15B	2.43B	2.31B	5.32
HLN Haleon Plc Adr	9.69	43.81B	14.26B	1.55B	0	0.3383
TAK Takeda Pharmaceutical Co Adr	13.10	41.53B	30.27B	1.93B	3.45B	0.6044
TEVA Teva Pharmaceutical Industries Ltd Adr	22.09	25.03B	16.77B	-959.00M	1.37B	-0.85
VTRS Viatris Inc	12.52	14.94B	15.05B	-883.30M	1.89B	-0.74

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-11-05	Hochstufung	Stifel	Hold → Buy
2024-06-17	Eingeleitet	TD Cowen	Buy
2024-03-19	Eingeleitet	Robert W. Baird	Outperform
2024-02-20	Herabstufung	UBS	Neutral → Sell
2023-11-20	Fortgesetzt	JP Morgan	Neutral
2023-10-24	Hochstufung	Evercore ISI	In-line → Outperform
2023-10-17	Eingeleitet	UBS	Neutral
2022-11-03	Hochstufung	Piper Sandler	Neutral → Overweight
2022-10-14	Hochstufung	BofA Securities	Underperform → Neutral
2022-08-16	Eingeleitet	Piper Sandler	Neutral
2022-04-22	Fortgesetzt	Goldman	Buy
2022-04-20	Eingeleitet	Goldman	Buy
2022-01-27	Hochstufung	Cantor Fitzgerald	Hold → Overweight
2021-12-01	Eingeleitet	Citigroup	Neutral
2021-10-07	Hochstufung	Jefferies	Hold → Buy
2021-09-02	Herabstufung	BofA Securities	Neutral → Underperform
2020-10-15	Hochstufung	Mizuho	Neutral → Buy
2020-07-30	Herabstufung	Goldman	Neutral → Sell
2020-02-14	Herabstufung	BofA/Merrill	Buy → Neutral
2020-02-14	Bestätigt	H.C. Wainwright	Neutral
2020-02-14	Herabstufung	JP Morgan	Overweight → Neutral
2020-02-06	Eingeleitet	Mizuho	Neutral
2020-01-31	Hochstufung	Wolfe Research	Underperform → Peer Perform
2019-09-05	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2019-07-15	Hochstufung	Goldman	Sell → Neutral
2019-05-31	Eingeleitet	H.C. Wainwright	Neutral
2019-05-01	Herabstufung	Citigroup	Buy → Neutral
2018-12-19	Herabstufung	Goldman	Neutral → Sell
2018-12-14	Eingeleitet	Wolfe Research	Underperform
2018-12-13	Herabstufung	Credit Suisse	Outperform → Underperform
2018-11-05	Eingeleitet	Piper Jaffray	Neutral
2018-08-07	Eingeleitet	Stifel	Hold
2018-06-21	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2018-06-06	Eingeleitet	B. Riley FBR, Inc.	Buy
2018-05-16	Hochstufung	Citigroup	Neutral → Buy
2018-05-11	Eingeleitet	BofA/Merrill	Buy

Alle ansehen

Alkermes Plc Aktie (ALKS) Neueste Nachrichten

Dec 20, 2024

Expansion Therapeutics Names Elliot Ehrich, MD, Chief Medical Officer - Marketscreener.com

Dec 20, 2024

Alkermes pays off and terminates major credit agreement By Investing.com - Investing.com Canada

Dec 20, 2024

2025 will be a big year for Mural Oncology's drugs in development - The Business Journals

Dec 20, 2024

Alkermes pays off and terminates major credit agreement - Investing.com

Dec 20, 2024

Tidal Investments LLC Invests $1.10 Million in Alkermes plc (NASDAQ:ALKS) - MarketBeat

Dec 20, 2024

Dec 19, 2024

Alkermes Prepares for New Flexibility Post Credit Termination - TipRanks

Dec 19, 2024

Geode Capital Management LLC Sells 60,037 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat

Dec 19, 2024

Dec 17, 2024

We Think Alkermes (NASDAQ:ALKS) Can Stay On Top Of Its Debt - Simply Wall St

Dec 17, 2024

Dec 16, 2024

Wilmington Savings Fund Society FSB Invests $582,000 in Alkermes plc (NASDAQ:ALKS) - MarketBeat

Dec 16, 2024

Barclays PLC Boosts Holdings in Alkermes plc (NASDAQ:ALKS) - MarketBeat

Dec 16, 2024

Dec 14, 2024

Alkermes To Take Part In The Fourth Annual Evercore ISI Healthconx Conference - Environmental Expert

Dec 14, 2024

Dec 13, 2024

Alkermes plc (NASDAQ:ALKS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Dec 11, 2024

Dec 10, 2024

Alkermes' EVP Craig Hopkinson sells shares worth $1.96 million By Investing.com - Investing.com South Africa

Dec 10, 2024

Frazier Life Sciences Management L.P. Acquires New Stake in Alkermes plc (NASDAQ:ALKS) - MarketBeat

Dec 10, 2024

Dec 09, 2024

Alkermes director Cato Laurencin sells $85,708 in stock By Investing.com - Investing.com Canada

Dec 09, 2024

Alkermes' EVP Craig Hopkinson sells shares worth $1.96 million - Investing.com

Dec 09, 2024

Dec 08, 2024

Wellington Management Group LLP Sells 1,696,507 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat

Dec 08, 2024

Alkermes plc (NASDAQ:ALKS) Stake Lifted by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat

Dec 08, 2024

Dec 06, 2024

Insider Sell: Craig Hopkinson Sells 9,221 Shares of Alkermes PLC (ALKS) - GuruFocus.com

Dec 06, 2024

Alkermes' chief medical officer sells $290,461 in stock By Investing.com - Investing.com Australia

Dec 06, 2024

Dec 05, 2024

Alkermes' chief medical officer sells $290,461 in stock - Investing.com India

Dec 05, 2024

Insider Sell: Craig Hopkinson Sells 14,349 Shares of Alkermes PL - GuruFocus.com

Dec 05, 2024

RTW Investments LP Sells 402,955 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat

Dec 05, 2024

BNP Paribas Financial Markets Buys 63,939 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat

Dec 05, 2024

Dec 04, 2024

Alkermes EVP and chief medical officer sells shares worth $441,550 By Investing.com - Investing.com Canada

Dec 04, 2024

Alkermes EVP and chief medical officer sells shares worth $441,550 - Investing.com

Dec 04, 2024